L'intérêt à découvert pour Verve Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Verve Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Verve Therapeutics (NASDAQ:VERV) Stock, Rapport sur les intérêts à découvert

VERVE THERAPEUTICS INC

Verve Therapeutics

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Verve Therapeutics Inc

MGI MEDIA & GAMES INVEST by MGI MEDIA & GAMES INVEST SE

Verve Group SE

Analysts' ratings for Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Regal Rexnord and provided 12-month price targets. The average target is $150.75, accompanied by a high estimate of $176.00 and a low estimate of $110.00. A decline of 9.73% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746738027_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regal Rexnord. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regal Rexnord. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regal Rexnord compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Regal Rexnord's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Regal Rexnord's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regal Rexnord analyst ratings.</a>
<h2>Get to Know Regal Rexnord Better</h2>
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.
<h3>A Deep Dive into Regal Rexnord's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Regal Rexnord's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -8.37%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Regal Rexnord's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.04% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.9%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Regal Rexnord's ROA stands out, surpassing industry averages. With an impressive ROA of 0.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Regal Rexnord's debt-to-equity ratio surpasses industry norms, standing at 0.85. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 8 Analysts Discuss Regal Rexnord Stock

Farmer Bros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.10) by 130 percent. This is a 666.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $82.05 million which missed the analyst consensus estimate of $88.98 million by 7.78 percent. This is a 3.87 percent decrease over sales of $85.36 million the same period last year.

Earnings

Earnings Misses

News

FARM

Farmer Bros Q3 EPS $(0.23) Misses $(0.10) Estimate, Sales $82.05M Miss $88.98M Estimate

In the current session, the stock is trading at $118.73, after a 2.17% increase. Over the past month, KKR Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) stock increased by 16.55%, and in the past year, by 15.13%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1746738022_0.png" alt="Past Year Chart" />

<h3>KKR P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
KKR has a better P/E ratio of 35.43 than the aggregate P/E ratio of 29.63 of the Capital Markets industry. Ideally, one might believe that KKR Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746738022_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: KKR

5 analysts have expressed a variety of opinions on Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Verisk Analytics and provided 12-month price targets. The average target is $319.6, accompanied by a high estimate of $335.00 and a low estimate of $297.00. Witnessing a positive shift, the current average has risen by 4.04% from the previous average price target of $307.20.
<img src="https://www.benzinga.com/files/images/story/2025/1746738019_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Verisk Analytics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$335.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$321.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$297.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$298.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$313.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Verisk Analytics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Verisk Analytics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Verisk Analytics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Verisk Analytics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Verisk Analytics analyst ratings.</a>
<h2>Get to Know Verisk Analytics Better</h2>
Verisk Analytics is the leading provider of statistical, actuarial, and underwriting data for the United States' property and casualty insurance industry. Verisk leverages a vast contributory database and proprietary data assets to develop analytical tools helping insurance providers to better assess and price risk, achieve operational efficiency and optimize claim settlement processes. While Verisk also offers tools to quantify costs after loss events occur and to detect fraudulent activity, it is expanding into adjacent markets of life insurance, marketing, and non-US operations.
<h3>A Deep Dive into Verisk Analytics's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Verisk Analytics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 8.62%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Verisk Analytics's net margin excels beyond industry benchmarks, reaching 28.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 105.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Verisk Analytics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.76%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 32.43, Verisk Analytics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

What 5 Analyst Ratings Have To Say About Verisk Analytics

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.35%. Currently, Brown &amp; Brown has a market capitalization of $31.97 billion. 
Buying $1000 In BRO: If an investor had bought $1000 of BRO stock 5 years ago, it would be worth $2,938.87 today based on a price of $111.53 for BRO at the time of writing.
<h3>Brown &amp; Brown's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746738017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Brown & Brown Stock In The Last 5 Years

Goldman Sachs BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSBD#NYSE">GSBD</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.43 by 4.65 percent. This is a 24.07 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $96.94 million which missed the analyst consensus estimate of $102.00 million by 4.96 percent. This is a 13.09 percent decrease over sales of $111.54 million the same period last year.

GSBD

Goldman Sachs BDC Q1 Adj. EPS $0.41 Misses $0.43 Estimate, Sales $96.94M Miss $102.00M Estimate

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) is looking for Q2 GAAP EPS of $0.20-$0.30 vs $0.24 analyst estimate. sees sales of $355.000 million-$390.000 million vs $376.68 million analyst estimate.

Guidance

Nu Skin Enterprises Sees Q2 GAAP EPS $0.20-$0.30 vs $0.24 Est; Sees Sales $355.000M-$390.000M vs $376.68M Est

SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) reported financial results for the first quarter after the market close on Thursday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/b45299834/soundhound-ai-reports-record-first-quarter-up-151-with-29-1-million-in-revenue">from the print</a>.
Q1 Earnings: SoundHound reported first-quarter revenue of $29.13 million, missing analyst <a href="http://benzinga.com/quote/soun/earnings">estimates</a> of $30.38 million, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The conversational AI company reported an adjusted loss of six cents per share, beating analyst estimates for a loss of nine cents per share.
Total revenue was up 151% on a year-over-year basis. The company said no customer accounted for more than&nbsp;10%&nbsp;of revenue in the quarter, highlighting revenue diversification. The company reported an adjusted EBITDA loss of $22.2 million. SoundHound ended the quarter with $246 million in cash and cash equivalents.
&#8220;SoundHound continues to extend its reach and create new possibilities for real-world AI applications. The release of our complete AI agent platform delivers full, voice-enabled Agentic AI for customers across all industries,&#8221; said Keyvan Mohajer, co-founder and CEO of SoundHound AI.
&#8220;At the same time, our bold growth initiatives are paying dividends, and we&#8217;re realizing significant cross-sell and upsell opportunities following our acquisitions.&#8221;
Outlook: SoundHound reaffirmed its full-year 2025 revenue guidance, continuing to expect full-year revenue in the range of $157 million to $177 million versus estimates of $166.17 million.
SoundHound&#8217;s management team will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
SOUN Price Action: <a href="https://www.benzinga.com/quote/SOUN" target="_blank" rel="noreferrer noopener">SoundHound AI shares</a> were down 3.80% in Thursday&#8217;s after-hours session, trading at $9.35 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45295132/nebius-stock-is-rallying-this-week-as-amazons-bezos-leads-funding-for-ai-data-unit">Nebius Stock Is Rallying This Week As Amazon&#8217;s Bezos Leads Funding For AI Data Unit</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

After-Hours Center

Movers

Tech

SOUN

SoundHound AI Stock Slides On Mixed Q1 Results, Reaffirms FY25 Outlook

ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.50) by 242 percent. This is a 1800 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $650.65 million which beat the analyst consensus estimate of $645.87 million by 0.74 percent. This is a 4.94 percent decrease over sales of $684.45 million the same period last year.

Earnings Beats

MODV

ModivCare Q1 Adj. EPS $(1.71) Misses $(0.50) Estimate, Sales $650.65M Beat $645.87M Estimate

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 48.28 percent increase over losses of $(0.29) per share from the same period last year.

RGLS

Regulus Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) affirms FY2025 Adj EPS guidance from $0.90-$1.30 to $0.90-$1.30 vs $0.99 analyst estimate. Affirms FY2025 sales outlook from $1.48 billion-$1.62 billion to $1.48 billion-$1.62 billion vs $1.48 billion estimate.

Nu Skin Enterprises Affirms FY2025 Adj EPS Guidance of $0.90-$1.30 vs $0.99 Est; Affirms FY2025 Sales Guidance of $1.48B-$1.62B vs $1.48B Est

PTMN

Portman Ridge Finance Q1 NII $0.47 Misses $0.63 Estimate, Total Inv Income $12.12M Miss $14.87M Estimate

Strattec Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRT#NASDAQ">STRT</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $0.95 by 38.95 percent. This is a 256.76 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $144.08 million which beat the analyst consensus estimate of $140.84 million by 2.30 percent. This is a 2.35 percent increase over sales of $140.77 million the same period last year.

STRT

Strattec Security Q3 EPS $1.32 Beats $0.95 Estimate, Sales $144.08M Beat $140.84M Estimate

Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 13.92 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $1.57 million which missed the analyst consensus estimate of $1.90 million by 17.21 percent. This is a 55.60 percent decrease over sales of $3.54 million the same period last year.

Avidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate

Options include AWS and Microsoft with artificial intelligence and data options
As cloud use cases continue to expand, Alaska Communications is teaming up with industry leader Slalom to provide advanced cloud offerings for Alaska enterprises and government organizations.
From enabling more efficient and sustainable exploration in the oil and gas industry to opening a world of real-time collaboration and learning opportunities in public education, managed cloud helps unlock innovation for Alaska.
Alaska Communications and Slalom offer services through Amazon Web Services (AWS) and Microsoft platforms, which include:
<ul>
<li>Planning and Migration - Evaluate cloud readiness. Plan and execute the move to the cloud.</li>
<li>Automation and Innovation - Build a digital operating model in the cloud, automate operations and compliance.</li>
<li>Optimization and Modernization - Tune cloud footprint for efficiency, cost and value.</li>
</ul>
This partnership also leverages Slalom's leadingartificial intelligence AI and data capabilities as added service offerings to help Alaska companies power their operations and gain a competitive advantage.
"Alaska's tough hiring market makes it challenging to find IT professionals with the specialized skills needed to operate cloud environments at peak efficiency," said Dale Knipp, senior vice president, business, Alaska Communications. "Alaska Communications is the gateway of modern technology for our clients in Alaska, and we're excited to help our clients maximize the benefits of cloud services, AI and data in the most cost-effective manner possible."
"To compete today, every business needs cloud technology," said Jayson Stangel, Managing Director, Slalom. "With Alaska Communications' deep knowledge of Alaska and its advanced fiber network combined with our expertise in cloud, AI and data consulting, customers can expect a tailored mix of services to support their unique needs and business goals."
"With a solid cloud foundation in place, the future is bright for Alaska enterprises and the services they provide to residents," said Knipp.

Contracts

ATNI

Alaska Communications And Slalom Enters Partnership To Deliver Managed Cloud Solutions For Alaska Enterprises

Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 7.89 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $3.67 million which missed the analyst consensus estimate of $4.38 million by 16.05 percent. This is a 76.88 percent decrease over sales of $15.89 million the same period last year.

ALEC

Alector Q1 EPS $(0.41) Beats $(0.48) Estimate, Sales $3.67M Miss $4.38M Estimate

WIIM

HUBS

HubSpot shares are trading lower after the company reported Q1 financial results. The company issued Q2 adjusted EPS guidance below estimates.

Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.10) by 90 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $23.71 million which beat the analyst consensus estimate of $23.07 million by 2.75 percent. This is a 33.69 percent increase over sales of $17.73 million the same period last year.

Rumble Q1 EPS $(0.01) Beats $(0.10) Estimate, Sales $23.71M Beat $23.07M Estimate

WOLF

Wolfspeed shares are trading lower. The company reported mixed Q3 financial results

Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.04 percent. This is a 37.5 percent increase over losses of $(0.32) per share from the same period last year.

SANA

Sana Biotechnology Q1 Adj. EPS $(0.20) Beats $(0.23) Estimate

Press Releases

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Health Care

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

General

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Management

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Comments

Verve Therapeutics

Intérêt court

Verve Therapeutics (NASDAQ:VERV) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL